Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

G9a/RelB regulates self-renewal and function of colon-cancer-initiating cells by silencing Let-7b and activating the K-RAS/β-catenin pathway

A Retraction to this article was published on 23 December 2016

This article has been updated

Abstract

Epigenetic reprogramming has been associated with the functional plasticity of cancer-initiating cells (CICs); however, the regulatory pathway has yet to be elucidated. A siRNA screen targeting known epigenetic genes revealed that G9a profoundly impairs the chemo-resistance, self-renewal and metastasis of CICs obtained from patients with colorectal cancer (CRC). Patients with elevated G9a were shown to face a high risk of relapse and poor survival rates. From a mechanistic perspective, G9a binds with and stabilizes RelB, thereby recruiting DNA methyltransferase 3 on the Let-7b promoter and repressing its expression. This leads to the activation of the K-RAS/β-catenin pathway and regulates self-renewal and function of CICs. These findings indicate that the G9a/RelB/Let-7b axis acts as a critical regulator in the maintenance of CIC phenotypes and is strongly associated with negative clinical outcomes. Thus, these findings may have diagnostic as well as therapeutic implications for the treatment of chemotherapy-resistant or metastatic CRC.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: G9a is crucial for the maintenance of CCICs.
Figure 2: G9a expression is positively correlated with metastasis and recurrence in patients with CRC.
Figure 3: G9a is required for functional maintenance of CCICs.
Figure 4: G9a regulates the tumorigenicity and metastasis of CCICs in vivo.
Figure 5: G9a blocks Let-7b miRNA expression, resulting in K-RAS/WNT/β-catenin pathway activation, and maintains the self-renewal capacity of CCICs.
Figure 6: G9a directly interacts with RelB in the Let-7b promoter through the ANK domain and stabilizes RelB through the ubiquitin-dependent pathway.
Figure 7: G9a interacts with RelB through the ANK domain and stabilizes RelB through the ubiquitin-dependent pathway.
Figure 8: Activation of the G9a/RelB/Let-7b/K-RAS signal axis correlates with poor outcome in patients with CRC.

Accession codes

Accessions

Gene Expression Omnibus

Change history

  • 21 November 2016

    In this Article, we reported that G9a promotes colorectal-cancer-initiating cell self-renewal and function by repressing Let-7b expression in a manner independent of its enzymatic activity, thereby activating K-RAS and β-catenin signalling. However, it has come to our attention that during figure assembly certain images were inappropriately processed and duplicated in several figures of the article, including Figs 1d, 2d, 3b, 5a, 5f, 6h and 8f. In light of these errors and image reuse in multiple figures we have no confidence in the accuracy of the reported data, and the conclusions of the paper may be affected. Therefore, we wish to retract the paper. We deeply regret these circumstances and apologize to the scientific community.

References

  1. 1

    Di Franco, S., Todaro, M., Dieli, F. & Stassi, G. Colorectal cancer defeating? Challenge accepted! Mol. Aspects Med. 39, 61–81 (2013).

    PubMed  Google Scholar 

  2. 2

    Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11–30 (2013).

    PubMed  Google Scholar 

  3. 3

    Markowitz, S. D. & Bertagnolli, M. M. Molecular basis of colorectal cancer. N. Engl. J. Med. 361, 2449–2460 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  4. 4

    Li, L., Cole, J. & Margolin, D. A. Cancer stem cell and stromal microenvironment. Ochsner J. 13, 109–118 (2013).

    PubMed  PubMed Central  Google Scholar 

  5. 5

    O’Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106–110 (2006).

    PubMed  Google Scholar 

  6. 6

    Abdul Khalek, F. J., Gallicano, G. I. & Mishra, L. Colon cancer stem cells. Gastrointest. Cancer Res. Suppl 1, S16–S23 (2010).

    Google Scholar 

  7. 7

    O’Brien, C. A. et al. ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21. Cancer Cell 21, 777–792 (2012).

    PubMed  Google Scholar 

  8. 8

    Crea, F., Danesi, R. & Farrar, W. L. Cancer stem cell epigenetics and chemoresistance. Epigenomics 1, 63–79 (2009).

    CAS  PubMed  Google Scholar 

  9. 9

    Todaro, M. et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of Interleukin-4. Cell Stem Cell 1, 389–402 (2007).

    CAS  Google Scholar 

  10. 10

    He, X. C. et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt–β-catenin signaling. Nat. Genet. 36, 1117–1121 (2004).

    CAS  PubMed  Google Scholar 

  11. 11

    Marusyk, A. & Polyak, K. Cancer cell phenotypes, in fifty shades of grey. Science 339, 528–529 (2013).

    CAS  PubMed  Google Scholar 

  12. 12

    Ying, Y. & Tao, Q. Epigenetic disruption of the WNT/β-catenin signaling pathway in human cancers. Epigenetics 4, 307–312 (2009).

    CAS  PubMed  Google Scholar 

  13. 13

    Vermeulen, L. et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468–476 (2010).

    CAS  PubMed  Google Scholar 

  14. 14

    Lao, V. V. & Grady, W. M. Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 8, 686–700 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  15. 15

    Kanwal, R. & Gupta, S. Epigenetic modifications in cancer. Clin. Genet. 81, 303–311 (2011).

    PubMed  PubMed Central  Google Scholar 

  16. 16

    Kreso, A. et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat. Med. 20, 29–36 (2014).

    CAS  PubMed  Google Scholar 

  17. 17

    Dow, L. E. et al. Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer. Cell 161, 1539–1552 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  18. 18

    You, J. S. & Jones, P. A. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22, 9–20 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  19. 19

    Cantone, I. & Fisher, A. G. Epigenetic programming and reprogramming during development. Nat. Struct. Mol. Biol. 20, 282–289 (2013).

    CAS  PubMed  Google Scholar 

  20. 20

    Hu, G. et al. A genome-wide RNAi screen identifies a new transcriptional module required for self-renewal. Genes Dev. 23, 837–848 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  21. 21

    David, R. Development: G9A covers all bases. Nat. Rev. Mol. Cell Biol. 14, 5 (2012).

    PubMed  Google Scholar 

  22. 22

    Shankar, S. R. et al. G9a, a multipotent regulator of gene expression. Epigenetics 8, 16–22 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  23. 23

    Li, B. et al. G9a co-localized with histone H3 lysine 9 monomethylation but not dimethylation in a nuclear membrane-dependent manner during mouse preimplantation embryo development. J. Assist. Reprod. Genet. 30, 441–448 (2012).

    PubMed  PubMed Central  Google Scholar 

  24. 24

    Tachibana, M. et al. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Gene Dev. 16, 1779–1791 (2002).

    CAS  PubMed  Google Scholar 

  25. 25

    Easwaran, H., Tsai, H.-C. & Baylin, S. B. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell 54, 716–727 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  26. 26

    Kobayashi, S. et al. LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells 30, 2631–2644 (2012).

    CAS  PubMed  Google Scholar 

  27. 27

    Westphalen, C. B. et al. Long-lived intestinal tuft cells serve as colon cancer-initiating cells. J. Clin. Invest. 124, 1283–1295 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  28. 28

    Kreso, A. et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat. Med. 20, 29–36 (2014).

    CAS  PubMed  Google Scholar 

  29. 29

    Yi, S.-Y., Hao, Y.-B., Nan, K.-J. & Fan, T.-L. Cancer stem cells niche: a target for novel cancer therapeutics. Cancer Treat. Rev. 39, 290–296 (2013).

    CAS  PubMed  Google Scholar 

  30. 30

    Yang, W.-H. et al. RAC1 activation mediates Twist1-induced cancer cell migration. Nat. Cell Biol. 14, 366–374 (2012).

    CAS  PubMed  Google Scholar 

  31. 31

    Muñoz, P., Iliou, M. S. & Esteller, M. Epigenetic alterations involved in cancer stem cell reprogramming. Mol. Oncol. 6, 620–636 (2012).

    PubMed  PubMed Central  Google Scholar 

  32. 32

    Gemei, M. et al. CD66c is a novel marker for colorectal cancer stem cell isolation, and its silencing halts tumor growth in vivo. Cancer 119, 729–738 (2013).

    CAS  PubMed  Google Scholar 

  33. 33

    Pang, R. et al. A subpopulation of CD26 + cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 6, 603–615 (2010).

    CAS  PubMed  Google Scholar 

  34. 34

    Chu, C.-Y. et al. Stromal cell-derived factor-1α (SDF-1alpha/CXCL12)-enhanced angiogenesis of human basal cell carcinoma cells involves ERK1/2-NF-κB/interleukin-6 pathway. Carcinogenesis 30, 205–213 (2009).

    CAS  PubMed  Google Scholar 

  35. 35

    Korinek, V. et al. Constitutive Transcriptional Activation by a β-Catenin–Tcf Complexin APC. Science 275, 1784–1787 (1997).

    CAS  PubMed  Google Scholar 

  36. 36

    Kumar, A. et al. Chemopreventive sphingadienes downregulate Wnt signaling via a PP2A/Akt/GSK3 pathway in colon cancer. Carcinogenesis 33, 1726–1735 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  37. 37

    Dembinski, J. L. & Krauss, S. Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin. Exp. Metastasis 26, 611–623 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  38. 38

    Moon, B.-S. et al. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling. J. Natl. Cancer Inst. 106, djt373 (2014).

    PubMed  Google Scholar 

  39. 39

    Li, K.-C. et al. Inhibition of G9a induces DUSP4-dependent autophagic cell death in head and neck squamous cell carcinoma. Mol. Cancer 13, 172–186 (2014).

    PubMed  PubMed Central  Google Scholar 

  40. 40

    Tao, H. et al. Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells. Mol. Cell. Biochem. 394, 23–30 (2014).

    CAS  PubMed  Google Scholar 

  41. 41

    Bhola, N. E. et al. Treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and notch-dependent cancer stem cell population. Cancer Res. 76, 440–452 (2016).

    CAS  PubMed  Google Scholar 

  42. 42

    Karamboulas, C. & Ailles, L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochim. Biophys. Acta 1830, 2481–2495 (2013).

    CAS  PubMed  Google Scholar 

  43. 43

    Morin, P. J. et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275, 1787–1790 (1997).

    CAS  Google Scholar 

  44. 44

    Nava, P. et al. IFN-induced suppression of β-catenin signaling: evidence for roles of Akt and 14.3.3. Mol. Biol. Cell 25, 2894–2904 (2014).

    PubMed  PubMed Central  Google Scholar 

  45. 45

    Roesch, A. et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141, 583–594 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  46. 46

    Ko, S. Y., Dass, C. R. & Nurgali, K. Netrin-1 in the developing enteric nervous system and colorectal cancer. Trends Mol. Med. 18, 544–554 (2012).

    CAS  PubMed  Google Scholar 

  47. 47

    Bu, P. et al. A microRNA miR-34a-regulated bimodal switch targets notch in colon cancer stem cells. Cell Stem Cell 12, 602–615 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  48. 48

    Hwang, W.-L. et al. MicroRNA-146a directs the symmetric division of Snail-dominant colorectal cancer stem cells. Nat. Cell Biol. 16, 268–280 (2014).

    CAS  PubMed  Google Scholar 

  49. 49

    Chen, P.-S. et al. miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. J. Clin. Invest. 121, 3442–3455 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  50. 50

    Kala, R., Peek, G. W., Hardy, T. M. & Tollefsbol, T. O. MicroRNAs: an emerging science in cancer epigenetics. J. Clin. Bioinformatics 3, 6–14 (2013).

    CAS  Google Scholar 

  51. 51

    Chen, M.-W. et al. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res. 70, 7830–7840 (2010).

    CAS  PubMed  Google Scholar 

  52. 52

    Dong, C. et al. Loss of FBP1 by snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 23, 316–331 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  53. 53

    Hua, K.-T. et al. The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis. Mol. Cancer 13, 189–202 (2014).

    PubMed  PubMed Central  Google Scholar 

  54. 54

    Tachibana, M. SET domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J. Biol. Chem. 276, 25309–25317 (2001).

    CAS  PubMed  Google Scholar 

  55. 55

    Caamaño, J., Alexander, J., Craig, L., Bravo, R. & Hunter, C. A. The NF-κB family member RelB is required for innate and adaptive immunity to Toxoplasma gondii. J. Immunol. 163, 4453–4461 (1999).

    PubMed  Google Scholar 

  56. 56

    Pettit, A. R. et al. Nuclear localization of RelB is associated with effective antigen-presenting cell function. Immunology 163, 4453–4461 (1997).

    Google Scholar 

  57. 57

    Shinkai, Y. & Tachibana, M. H3K9 methyltransferase G9a and the related molecule GLP. Genes Dev. 25, 781–788 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  58. 58

    Liu, F. et al. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J. Med. Chem. 52, 7950–7953 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  59. 59

    Smith, J. J. et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 138, 958–968 (2010).

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank C.-S. Chen (Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan) for the gift of K-RASG12D and K-RASG12V plasmid. We also thank the Technology Commons in the College of Life Science and Center for Systems Biology, National Taiwan University, for instrument support for cell sorting. This work was supported by grants from the National Science Council, Taiwan (NSC 099-2811-C-099-003; NSC 100-2811-C-099-003; NSC 102-2321-B-002-034), the Ministry of Science and Technology, Taiwan (MOST 104-231-B-002-006; MOST 104-2320-B-002-070-MY3; MOST 104-2911-I-002-302); and National Taiwan University (NTU 104-R7559-6; NTU 104R8952-1; NTU 104R7602).

Author information

Affiliations

Authors

Contributions

S.-T.C. and M.-L.K. conceived and designed the experiments. S.-T.C. analysed the data with the assistance of C.-T.T. and B.-Z.L. for the clinical data analysis. S.-T.C., M.-L.K. and C.-C.C. wrote the paper with assistance from C.-Y.C. W.-J.L. designed and carried out in vivo work and a portion of the plasmid construction. The sample collection and treatment of CRC patients were performed by B.-Z.L. M.-T.L. carried out the sample collection and supervised this work. M.-L.K. designed and supervised this work.

Corresponding authors

Correspondence to Ming-Tsan Lin or Min-Liang Kuo.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Integrated supplementary information

Supplementary Figure 1 Validation of the stem-like and differentiation properties in LGR5-RFP+ and CK20-GFP+ cells.

(a) RT-qPCR for the stemness gene (left panel) and differentiation gene (right panel) in LGR5-RFP+ and CK20-GFP+cells. Data represent mean ± S. D. n = 3 independent experiment (each experiment contains 3 technical replicates). (b) Sphroid formation (left panel) and TOP/FOP reporter activity (right panel) in LGR5-RFP+ and CK20-GFP+cells. Data represent mean ± S. D. n = 3 independent experiment (each experiment contains 3 technical replicates). (c) RT-qPCR to illustrated the mRNA levels of knockdown efficacy of 19 epigenetic regulators. Data represent mean ± S. D. n = 3 independent experiment (each experiment contains 3 technical replicates).

Supplementary Figure 2 G9a activate AKT signalling and β-catenin phosphorylation in K-RAS mutant CCICs.

(a) Western blotting analysis of indicated antibody in CCICs versus non-CCICs in APC wt and mutated CRC cells. (b) Let-7b expression in (a). n = 3 for each group; P < 0.01 by Student’s t-test. (c) Upper: Western blot analysis of p-AKT, AKT, p- β-catenin and β-catenin in K-RAS wildtype and mutated CRC cells treatment with different dosage of specific PI3K inhibitor, XL147. Lower: TOP/FOP activity assay. Data represent mean ± S. D. n = 3 independent experiment (each experiment contains 3 technical replicates). (d) Western blot analysis of p-AKT, AKT, p- β-catenin and β-catenin in K-RAS wildtype and mutated CRC cells transient transfection with shAKT plasmid. Lower: TOP/FOP activity assay. Data represent mean ± S. D. n = 3 independent experiment (each experiment contains 3 technical replicates). (e) RT-qPCR of K-RAS expreesion in CD133 and CD133+ cells. Uncropped images of blots of a, c, d, are shown in Supplementary Fig. 6.

Supplementary Figure 3 ChIP-Seq analysis.

(a) Chip-Seq peaks over chromosomes. (b) Overlap between the top 20,000 genomic location (1-kb windown) bounds by G9a, H3K9me2 and shG9a-reexpressed DNG9a as determined using Illumina. GEO accession number: GSE82131.

Supplementary Figure 4 GLP, the obligatory G9a partner, plays as a bridge to stabilize G9a protein in functional roles in CCICs.

(a) Upper: Western blot analysis of G9a, GLP, H3K9me2 and RelB in CCICs transient transfection with shG9a, shGLP, G9a or DNG9a. Lower: sphere formation analysis. n = 3 independent experiments (each experiment contains 5 technical replicates). (b) Upper: Western blot analysis of G9a, GLP, H3K9me2 and RelB in CCICs transient transfection with shGLP, G9a and DNG9a. Lower: sphere formation analysis. n = 3 independent experiments (each experiment contains 5 technical replicates). (c) Western blot analysis of G9a, GLP, H3K9me2, RelB, K-RAS, p-β-catenin and β-catenin in CCICs transfection with shG9a GLP expression plasmid. (d) RT-qPCR for Let-7b expression in (c). n = 3 independent experiment (each experiment contains 3 technical replicates). (e) TOP/FOP activity assay in (c). Data represent mean ± s.d.n = 3 independent experiment (each experiment contains 3 technical replicates). (f) Sphere formation analysis in (c). n = 3 (each experiment contains 5 technical replicates). (g) Uncropped images of blots of ac are shown in Supplementary Fig. 6.

Supplementary Figure 5 Two shRNA sequence to target G9a and GLP to avoid off-target effects.

(a) Western blot analysis of G9a, GLP, H3K9me2, RelB, KRAS, p-β-catenin and β-catenin in CCICs transfection with two different sequence of shG9a and shGLP plasmid in CCICs. (b) RT-qPCR for Let-7b expression in (a). n = 3 independent experiment (each experiment contains 3 technical replicates). (c) TOP/FOP activity assay in (a). Data represent mean ± S. D. n = 3 independent experiment (each experiment contains 3 technical replicates). (d) Sphere formation in (a) n = 3 (each experiment contains 5 technical replicates). (e) Representative image of immunohistochemical staining for G9a, RelB and K-RAS. Scale bars, 200 μm. (g) G9a-RelB-Let-7b-K-RAS-β-catenin signalling in CCICs.

Supplementary information

Supplementary Information

Supplementary Information (PDF 16199 kb)

Supplementary Table 1

Supplementary Information (XLSX 67 kb)

Supplementary Table 2

Supplementary Information (XLSX 73 kb)

Supplementary Table 3

Supplementary Information (XLSX 33 kb)

Supplementary Table 4

Supplementary Information (XLSX 42 kb)

Supplementary Table 5

Supplementary Information (XLSX 45 kb)

Supplementary Table 6

Supplementary Information (XLS 55 kb)

Supplementary Table 7

Supplementary Information (XLS 35 kb)

Supplementary Table 8

Supplementary Information (XLSX 86 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cha, ST., Tan, CT., Chang, CC. et al. G9a/RelB regulates self-renewal and function of colon-cancer-initiating cells by silencing Let-7b and activating the K-RAS/β-catenin pathway. Nat Cell Biol 18, 993–1005 (2016). https://doi.org/10.1038/ncb3395

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing